According to CellSeed's latest earnings report, sales for the interim period of the fiscal year ending December 2026 declined sharply year on year and the company remained in the red, while the exercise of stock acquisition rights raised funds and increased cash on hand.
The stock traded at ¥224 at the close on 30 September, up ¥7 from the previous day. Since mid-September, it has continued to move sideways at around ¥226, with trading over the past 5 business days also confined to a narrow range. Trading volume increased to 87,900 shares on 28 September, but the share price recorded only limited gains.
According to the earnings report summary, sales for the interim period of the fiscal year ending December 2026 fell 43.7% year on year to ¥20.82 million, while the interim net loss for the same period was ¥610.61 million, and substantial doubt regarding the going-concern assumption continued. The exercise of stock acquisition rights raised approximately ¥1.1 billion, increasing cash on hand to approximately ¥1.79227 billion.
Key points to monitor in future performance include the conversion of regenerative medicine CDMO projects into contracts and progress in Phase 3 trials. At the same time, uncertainty over approval timing and cash-flow challenges remain risk factors. The earnings report update includes an analysis of factors that could contribute to medium- to long-term performance, alongside the potential for stabilizing the financial base and expanding the business.
Overall, the report cites positive factors including progress in clinical trials for allogeneic cartilage cell sheets, differentiation through patent acquisitions, expansion of contract work using CPCs and the securing of working capital through fundraising. It also identifies several risk factors, including uncertainty over approval timing, the impact of capital policy and the risk of delays in research and development.